Creo Medical Group Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Creo Medical Group şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-3.3%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-3.3%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Creo Medical Group PLC (LON:CREO) Screens Well But There Might Be A Catch

Sep 19

Market Cool On Creo Medical Group PLC's (LON:CREO) Revenues Pushing Shares 26% Lower

Mar 02

Revenues Tell The Story For Creo Medical Group PLC (LON:CREO) As Its Stock Soars 29%

Dec 29

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: CREO şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: CREO şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Creo Medical Group Piyasaya Karşı Temettü Getirisi

CREO temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (CREO)	n/a
Pazarın Alt %25'i (GB)	2.2%
Pazarın En İyi %25'i (GB)	6.0%
Sektör Ortalaması (Medical Equipment)	2.7%
Analist tahmini (CREO) (3 yıla kadar)	0%

Önemli Temettü: CREO şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, CREO şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: CREO şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: CREO herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Creo Medical Group Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

New minor risk - Shareholder dilution

Consensus EPS estimates fall by 24%

Chairman recently bought UK£700k worth of stock

Price target decreased by 28% to UK£0.57

New minor risk - Market cap size

Consensus EPS estimates fall by 11%

First half 2024 earnings released: UK£0.034 loss per share (vs UK£0.044 loss in 1H 2023)

New minor risk - Shareholder dilution

No longer forecast to breakeven

New minor risk - Share price stability

Micro-Tech (NL) International B.V. entered into a binding agreement to acquire 51% stake in Creo Medical, S.L.U. from Creo Medical Group PLC (AIM:CREO) for €36.7 million.

Creo Medical Group PLC (LON:CREO) Screens Well But There Might Be A Catch

New major risk - Financial position

Creo Medical Group PLC, Annual General Meeting, Jun 26, 2024

Consensus EPS estimates fall by 21%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Creo Medical Group plc Announces Board Changes

Forecast to breakeven in 2026

New minor risk - Financial data availability

Creo Medical Group PLC to Report Fiscal Year 2023 Results on May 15, 2024

New minor risk - Profitability

Market Cool On Creo Medical Group PLC's (LON:CREO) Revenues Pushing Shares 26% Lower

Creo Medical Group plc Announces Microwave Lung Ablation Update

New minor risk - Share price stability

Creo Medical Group plc Announces Continued Progress on the Phased Market Release of Its Latest Device, Speedboat® UltraSlim

Forecast to breakeven in 2026

Revenues Tell The Story For Creo Medical Group PLC (LON:CREO) As Its Stock Soars 29%

Creo Medical Group plc Announces First Use of Speedboat UltraSlim in the USA

Creo Medical Group PLC Announces the Initiation of Its Commercial Launch of Speedboat Ultraslim

Creo Medical Group plc Receives 510(K) Clearance from the Us Food & Drug Administration for Its Speedboat Ultraslim Device

Creo Medical Group plc Announces EU Launch Accelerated by 18 Months Eu Regulatory Pathway for Launch Early 2024

Is Creo Medical Group (LON:CREO) Weighed On By Its Debt Load?

First half 2023 earnings released: UK£0.044 loss per share (vs UK£0.074 loss in 1H 2022)

Creo Medical Group PLC to Report First Half, 2023 Results on Sep 12, 2023

Creo Medical Group PLC, Annual General Meeting, Jun 27, 2023

Creo Medical Group plc Announces First In-Human Milestone Reaches for Microblate Flex as Part of Lung Tissue Ablation Clinical Study

Full year 2022 earnings: EPS misses analyst expectations

Key Executive recently bought UK£543k worth of stock

Creo Medical Group PLC, Annual General Meeting, Mar 08, 2023

Creo Medical Group PLC has completed a Follow-on Equity Offering in the amount of £28.5 million.

Creo Medical Group PLC, Annual General Meeting, Mar 08, 2023

Less than half of directors are independent

Creo Medical Limited, Annual General Meeting, Jun 28, 2022

Creo Medical Limited to Report Fiscal Year 2021 Results on May 23, 2022

Less than half of directors are independent

Creo Medical Limited has completed a Follow-on Equity Offering in the amount of £5.06601 million.

Creo Medical Limited has completed a Follow-on Equity Offering in the amount of £31.250001 million.

New 90-day high: UK£2.23

Creo Medical (LON:CREO) Is In A Good Position To Deliver On Growth Plans

New 90-day high: UK£2.12

Creo Medical Group plc Receives US FDA clearance for MicroBlate™ Flex device

How Many Creo Medical Limited (LON:CREO) Shares Do Institutions Own?

New 90-day high: UK£2.08

New 90-day low: UK£1.67

First half earnings released

New 90-day low: UK£1.72

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin